Fatigue Clinical Trial
Official title:
Eszopiclone for Improving Sleep Continuity in MS Patients With Sleep Disturbances and Its Impact on Daytime Fatigue
Verified date | December 2008 |
Source | University of Vermont |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
The purpose of this study is to determine if people with multiple sclerosis (MS) and fatigue
have disrupted sleep, as was suggested in previous studies, and whether treating the
disruptions of sleep improves the fatigue.
Eszoplicone, a new drug FDA approved for the treatment of insomnia, will be used to control
sleep disturbances in MS patients with fatigue.
The study will last 7 weeks, 5 of which will involve being on medication. You will take
eszopiclone or placebo (sugar pill), keep a sleep diary and wear an actigraph, a device
about the size of a digital watch that monitors and records sleep activity. You will
randomly be chosen to get either placebo or medication. Half the subjects will get placebo
and half eszopiclone. The decision will be made by a pharmacist (who does not know you)
according to a randomization table. Neither you nor the investigating physician will know
whether you are on sugar pill or medication. At both the beginning and the conclusion of the
study you will be asked to fill out 2 questionnaires to evaluate fatigue and depression and
undergo some memory and speech tests. The testing will take about 2 hours. Actigraphy is a
wrist-worn, watch like device that records activity during waking and sleeping without
application of any sensors. It consists of a movement detector, so it can record movement
and non-movement data for a week or two. You should wear it continuously during wakefulness
and sleep as you go about routine daily activities. You should only take it off if you are
going to shower, bathe or swim. A sleep log is a graph on which, for 2 to 3 weeks, you will
record bedtime, approximate sleep time, times and duration of awakenings during the sleep
period, final awakening time, and naps taken during the day to the best of your knowledge.
You will also be asked to avoid getting pregnant. If you are a woman who may have the
potential to get pregnant then a pregnancy test may be performed at the beginning of the
study, before you receive the medication, at the first follow up visit and when you end the
study.
Status | Completed |
Enrollment | 30 |
Est. completion date | June 2008 |
Est. primary completion date | May 2008 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 64 Years |
Eligibility |
Inclusion Criteria: 1. Male or female subjects ages 18 - 64 inclusive. 2. Female subjects must be surgically sterile, at least 1 year post menopausal, or agree to use a medically acceptable form of birth control throughout the study and for 2 weeks following the last study visit. 3. Diagnosis of relapsing-remitting MS 4. MS and MS symptoms must be stable (no evidence of worsening or of exacerbations) for at least 3 months prior to screening visit. The date of last recorded exacerbation will be captured at enrollment. 5. EDSS score </= 5 6. Diagnosis of fatigue based on fatigue questionnaires, specifically the Fatigue Descriptive Scale (FDS) in which a score of five higher is considered to be indicative of fatigue (range 0-13) 7. Actigraphic evidence of sleep disturbances defined a sleep latency of 30 minutes or longer, and/or total sleep time of less than 6.5 hours. 8. Finally a CESD score of under 20 (20 or more is suggestive of Major Depression) Exclusion Criteria: 1. Pregnant and breast-feeding women 2. Subjects with any history of substance and/or alcohol abuse or dependence within 5 years prior to screening. 3. Subjects who are the sole caretaker of infants and young children because they may be too sedated in the middle of the night in case they need to get up and take care of an infant or a child. 4. Patients with past history of allergy to eszopiclone or Zopiclone. 5. Patients with primary progressive Multiple Sclerosis. 6. Subjects with impaired cognition as measured by Mini Mental State Examination (MMSE) score of 26 or less 7. Subjects with history suggestive of another primary sleep disorder including OSAS, PLMS, or RLS 8. Any patients with any known active DSM-IV axis I (i.e. schizophrenia, etc) or any other psychiatric disorder which would compromise the investigator's ability to evaluate the safety and efficacy of the study medication. 9. Patients 65 years old and older because the drug at the 3 mg dose has not been FDA approved to be used in this age group. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | University of Vermont | Burlington | Vermont |
Lead Sponsor | Collaborator |
---|---|
University of Vermont |
United States,
Attarian HP, Brown KM, Duntley SP, Carter JD, Cross AH. The relationship of sleep disturbances and fatigue in multiple sclerosis. Arch Neurol. 2004 Apr;61(4):525-8. — View Citation
Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis. 1994 Jan;18 Suppl 1:S79-83. — View Citation
Iriarte J, Katsamakis G, de Castro P. The Fatigue Descriptive Scale (FDS): a useful tool to evaluate fatigue in multiple sclerosis. Mult Scler. 1999 Feb;5(1):10-6. — View Citation
Jean-Louis G, Mendlowicz MV, Gillin JC, Rapaport MH, Kelsoe JR, Zizi F, Landolt H, von Gizycki H. Sleep estimation from wrist activity in patients with major depression. Physiol Behav. 2000 Jul 1-15;70(1-2):49-53. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Fatigue | 7 weeks | No | |
Secondary | Sleep continuity | 7 weeks | No | |
Secondary | Neurocognitive function | 7 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04959214 -
The Effect Of Progressıve Relaxatıon Exercıses
|
N/A | |
Recruiting |
NCT04984226 -
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
|
Phase 2 | |
Completed |
NCT04531891 -
Utility and Validity of a High-intensity, Intermittent Exercise Protocol
|
N/A | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Completed |
NCT04960865 -
Kinesio Taping and Calf Muscle Fatigue
|
N/A | |
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT06421233 -
The Effect of Endorphin Massage Applied to Postpartum Women on Anxiety and Fatigue Levels
|
N/A | |
Active, not recruiting |
NCT05344183 -
Immediate and Short-term Effects of Low-level Laser
|
N/A | |
Completed |
NCT04716049 -
Effectiveness of Recovery Protocols in Elite Professional Young Soccer Players
|
N/A | |
Completed |
NCT00060398 -
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT05241405 -
Evaluation of the Impact of Taking American Ginseng for 8 Weeks on Fatigue in Patients Treated for Localized Breast Cancer
|
N/A | |
Active, not recruiting |
NCT06074627 -
Radicle Energy2: A Study of Health and Wellness Products on Fatigue and Other Health Outcomes
|
N/A | |
Completed |
NCT03943212 -
The Effect of Blood Flow Rate on Dialysis Recovery Time in Patients Undergoing Maintenance Hemodialysis
|
N/A | |
Recruiting |
NCT05567653 -
Effects of Probiotics on Gut Microbiota, Endocannabinoid and Immune Activation and Symptoms of Fatigue in Dancers
|
N/A | |
Active, not recruiting |
NCT05636696 -
COMPANION: A Couple Intervention Targeting Cancer-related Fatigue
|
N/A | |
Not yet recruiting |
NCT05863897 -
e-COGRAT: A Blended eHealth Intervention for Fatigue Following Acquired Brain Injury
|
N/A | |
Not yet recruiting |
NCT05002894 -
Effect of Pilates Exercises On Fatigue In Post Menopausal Women
|
N/A | |
Recruiting |
NCT04091789 -
Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea
|
Phase 2 | |
Completed |
NCT02911649 -
Reducing Sedentary Behaviour With Technology
|
N/A | |
Completed |
NCT03216616 -
Guided Self-Management Intervention Targeting Fatigue in Rheumatic Inflammatory Diseases
|
N/A |